Co-Authors
This is a "connection" page, showing publications co-authored by Alessandro Armuzzi and Gionata Fiorino.
Connection Strength
0.909
-
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. Inflamm Bowel Dis. 2020 10 23; 26(11):e134-e136.
Score: 0.227
-
The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. Aliment Pharmacol Ther. 2018 11; 48(9):941-950.
Score: 0.197
-
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm Bowel Dis. 2017 02; 23(2):233-243.
Score: 0.176
-
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. United European Gastroenterol J. 2020 12; 8(10):1228-1235.
Score: 0.057
-
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020 07; 69(7):1213-1217.
Score: 0.055
-
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. Eur J Gastroenterol Hepatol. 2019 Nov; 31(11):1361-1369.
Score: 0.053
-
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. Dig Liver Dis. 2019 04; 51(4):510-515.
Score: 0.050
-
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. Inflamm Bowel Dis. 2018 10 12; 24(11):2442-2451.
Score: 0.049
-
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion. 2017; 96(3):166-172.
Score: 0.046